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SCIENTIFIC REPORT
Complications of mitomycin C therapy in 100 eyes with
ocular surface neoplasia
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Aim: To determine the complications associated with mito-
mycin C (MMC) in the treatment of ocular surface neoplasia.
Methods: A retrospective and consecutive study of 100 eyes
in 91 patients with ocular surface neoplasia treated with
MMC in a single centre between November 1998 and
January 2005. Outcome measures included complications of
MMC and the treatment required for these complications.
Results: One to three 7 day cycles of topical MMC 0.04%
four times a day were given to 59 eyes with localised
corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes
with diffuse CIN, six eyes with recurrent CIN, one eye with
ocular surface squamous cell carcinoma, three eyes with
primary acquired melanosis (PAM) with atypia, nine eyes
with conjunctival malignant melanoma (MM), two eyes with
sebaceous carcinoma with pagetoid spread, and one eye
with recurrent atypical fibroxanthoma. Nine patients had
bilateral CIN. 31 (34%) cases developed an allergic reaction
to MMC and 14 (14%) eyes had epiphora secondary to
punctal stenosis at a mean follow up period of 26.5 months.
Conclusion: In the largest study looking at complications of
topical MMC in the treatment of ocular surface neoplasia,
allergic reaction and punctal stenosis are relatively common.
Serious complications were not observed suggesting the safe
use of MMC in mid-term follow up.
T
opical mitomycin C (MMC) has been well described for
the treatment of corneal-conjunctival intraepithelial
neoplasia (CIN),1–4 primary acquired melanosis (PAM)
with atypia,5–7 conjunctival malignant melanoma (MM),6 7
and pagetoid spread of sebaceous carcinoma.8
We present a large series of 100 eyes with ocular surface
neoplasia treated with MMC either as primary or adjunctive
therapy. The aim of this study was to determine the
complications of MMC associated with the treatment of
ocular surface neoplasia.
METHODS
A retrospective and consecutive study was carried out of 100
eyes in 91 patients (67 males and 24 females) with ocular
surface neoplasia receiving MMC therapy in a single centre
between November 1998 and January 2005. Nine patients
had bilateral CIN. There were 59 eyes with localised CIN, 19
eyes with diffuse CIN, six eyes with recurrent CIN, one eye
with squamous cell carcinoma, three eyes with PAM with
atypia, nine eyes with conjunctival melanoma, two eyes with
sebaceous carcinoma, and one eye with recurrent atypical
fibrous histiocytoma. All diagnoses were confirmed by
histopathology. Cases were excluded if the follow up was
less than 3 months.
Most patients were treated with MMC 0.04% four times a
day using a week on and week off regimen. Treatment was
only commenced after complete epithelial healing was
achieved. Punctal plugs were not used during MMC treat-
ment in any of our cases. The treatment in all cases was
undertaken by a single ocular oncologist (JM). The treatment
regimens for localised and diffuse CIN, diffuse PAM with
atypia, and recurrent conjunctival MM are summarised in
table 1. Patients from rural areas with difficult access to the
treatment centre were treated with a continuous 2 week
course of MMC. Two cases of sebaceous carcinoma had
surgical excision and cryotherapy followed by three courses
of adjunctive MMC. A single case of recurrent atypical fibrous
histiocytoma was treated by three courses of MMC after
primary surgical excision. MMC is not routinely used for the
treatment of squamous cell carcinoma (SCC) in our centre,
however a 1 week course of MMC was given in a patient
following excision owing to a delay in the application of b
radiotherapy.
Patients were examined in most cases 1 month and
3 months following completion of MMC treatment, then at
6 monthly intervals. Outcome measures included complica-
tions of MMC and the treatment required for these
complications. Allergic reaction was defined clinically as
marked pruritus in association with conjunctival and
periocular erythema and oedema. Punctal stenosis was
detected clinically with inspection of the punctum using slit
lamp biomicroscopy. Probing and syringing of the nasolacri-
mal system was undertaken in all eyes with epiphora.
Transient tearing, irritation, and conjunctival erythema were
regarded as self limiting reactions and not complications of
MMC.
Data were entered into an Excel database and analysed
with SAS (SAS institute Inc, Cary, NC, USA) version 9.1.
Binary outcomes were analysed using log binomial general-
ised estimating equation (GEE) allowing clustering of
patients. A p value of ,0.05 was considered significant.
RESULTS
The mean duration of follow up was 26.5 months (range 3–
69, median 20.5) (fig 1); 31 (34%) cases developed an allergic
reaction towards MMC. Allergy occurred during the second
(10) or third course (21) of MMC (table 2). In 19 of these
cases, the particular week’s course of MMC was completed.
In the other 12 cases, MMC was immediately held because of
poor tolerance towards the allergic symptoms. In all patients,
the allergic symptoms and signs settled within a week with
cold compresses and topical lubricants.
Fourteen eyes (14%) in 14 patients developed epiphora as a
result of punctal stenosis after application of MMC. The
mean duration from the first day of MMC treatment to the
onset of epiphora was 1.9 months (range 0.75–4, median
1.75). Epiphora were reported by all patients at their first
Abbreviations: CIN, corneal-conjunctival intraepithelial neoplasia;
MM, malignant melanoma; MMC, mitomycin C; PAM, primary acquired
melanosis; SCC, squamous cell carcinoma
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follow up review following completion of MMC. The
appointment date rather than the exact date of onset of
epiphora was used to calculate our results. The frequency of
epiphora by the number of completed courses of MMC is
presented in table 3. Twelve of the 14 patients did not have a
previous history of epiphora. Two patients with pre-existing
epiphora due to ectropion and punctal stenosis noted
worsening of their symptom following MMC treatment.
Seven patients underwent dilatation and syringing of the
punctum and five patients required a punctal one snip
procedure to achieve resolution of the epiphora. One patient
had persistent minor tearing despite syringing but was not
troubled by the symptom, and one patient had persistent
tearing after punctal snip that subsequently required dacro-
cystorhinostomy. The punctum in each patient remained
patent throughout the follow up period. Using type 3 GEE
analysis, an allergic reaction did not predict the occurrence of
punctal stenosis (p.0.05).
One patient developed ptosis as a result of levator
disinsertion attributed to allergy related lid oedema. At no
stage was limbal stem cell deficiency, corneoscleral ulcera-
tion, iridocyclitis, cataract, or glaucoma observed in any of
the patients.
DISCUSSION
Before its use in ocular surface neoplasia, MMC had been
widely used in glaucoma and pterygium surgery for its anti-
proliferative effect on subconjunctival fibroblasts. In 1994,
Frucht-Pery et al were credited for first using MMC in the
treatment of corneal intraepithelial neoplasia.9 MMC has a
few advantages in the treatment of ocular surface neoplasia.
Unlike cryotherapy, it is a ‘‘whole eye’’ treatment, spreading
to cover the entire ocular surface and reaching well into the
fornices, thereby potentially eradicating subclinical new
tumours on the ocular surface. MMC is considered a safe
chemotherapeutic agent in treating ocular surface neoplasia.
Transient side effects including tearing, ocular pain, blephar-
ospasm, keratoconjunctivitis, conjunctival hyperaemia, and
punctate epithelial keratopathy are common.1 4 6 8–10
Uncommon but significant complications such as limbal
stem cell deficiency, focal corneal haze, cataract, excoriating
dermatitis, and disciform keratitis have also been reported
(table 4).2 6 7 11 12
Our study is the largest cohort to date looking at
complications of topical MMC. We found that allergic
reaction is the most common complication (34%). This has
not been previously reported as a common complication. One
study suggested possible allergy due to MMC in two of 17
patients (12%) with CIN.1 Three patients from two separate
studies were reported as having toxoallergic reactions
following MMC treatment.13 14 Interestingly, we found that
the incidence of allergic reaction was greatest among patients
with conjunctival melanoma (eight of nine cases).
A delayed hypersensitivity reaction could be a possible
mechanism for the allergic reaction of the ocular surface to
MMC. Firstly, the allergic reaction was always observed after
the second or third courses of MMC in our study and never
during the first course. Patients who developed an allergy
were likely to be sensitised during the first course of
treatment. Secondly, the process of sensitisation requires
cells to present antigen to T lymphocytes and this role could
be fulfilled by Langerhan cells found in the conjunctiva.
Contact allergy to MMC, presenting as exfoliative derma-
titis of the palms and soles or generalised itch, has occurred
with intravesical instillation or topical application.15–17 Patch
tests with MMC concentrations as low as 0.01% in these
patients was positive, suggesting a type IV hypersensitivity
reaction which is cell mediated.15–17 Type III hypersensitivity
reactions have also been reported with MMC.15 Further
studies are needed to evaluate the mechanisms of allergic
reaction to MMC on the ocular surface.
Epiphora secondary to punctal stenosis was the next most
commonly encountered complication (14%) in our study.
Two cases (12.5%) had persistent epiphora, possibly due to
more distal obstruction of the nasolacrimal apparatus. The
incidence may have been lower if we had used punctal
occlusion routinely, but then we would have been unneces-
sarily inserting punctal plugs into over 80% of our patients.
Punctal-canalicular obstruction was first reported with MMC
Table 1 Summary of treatment regimen of ocular
surface neoplasia
Treatment group Treatment regimen
Localised CIN Excision and 0.04% MMC four times
daily 2–3 weeks, 1 week on/1 week off
Diffuse CIN 0.04% MMC four times daily 3 weeks, 1
week on/1 week off
Diffuse PAM with atypia 0.04% MMC four times daily 3 weeks, 1
week on/1 week off
Recurrent conjunctival MM Excision and 0.04% MMC four times




























Figure 1 Distribution of duration of follow up of the 100 eyes with
ocular surface neoplasia treated with MMC.







No 1 31 28 60
100% 77% 57%
Yes 0 10 21 31
0% 24% 43%
Total 1 41 49 91







No 3 43 40 86
75% 81% 93%
Yes 1 10 3 14
25% 19% 7%
Total 4 53 43 100
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in a patient with corneal epithelial dysplasia 1 month after
treatment.13 In another study, punctal-canalicular obstruc-
tion was noted in 43% of patients treated for PAM, MM,
and recurrent SCC 1 month after completion of MMC.14
Punctal stenosis was an unexpected complication of MMC
given its effectiveness as an adjunct to punctectomy in
preventing punctal restenosis.18 However, obstruction of
the punctum and canaliculus has been well reported with
other chemotherapeutic agents such as systemic fluo-
rouracil, S-1, and docetaxel, which are secreted into the
tears thereby inducing chronic inflammation and subsequent
fibrosis.19–21 Inflammation from toxallergic reaction was
thought to be a possible mechanism underlying MMC
related punctual-canalicular stenosis in one study13;
however, our study showed that there was no significant
correlation between allergic reaction and punctal stenosis
complications to support this hypothesis. Further studies are
necessary to evaluate the mechanism underlying punctal
stenosis.
Patients with underlying mild punctal stenosis should be
warned of the potential onset or exacerbation of epiphora if
MMC treatment is planned. Fortunately, the management of
punctal stenosis was mostly straightforward and uncompli-
cated. In 44% of cases epiphora resolved following simple
dilatation of the punctum with syringing of the nasolacrimal
system; 33% required a punctal snip to the posterior lip of the
lower lid punctum. Long term follow up is necessary to
determine if punctal stenosis or restenosis may occur later.
In one of our cases of diffuse CIN involving 360˚of limbus
and near total corneal involvement, the whole corneal
epithelium sloughed off after first course of MMC as a result
of complete destruction and shedding of the lesion. A second
course of MMC was subsequently given following epithelial
healing without development of an epithelial defect.
Peripheral pannus and recurrent corneal epithelial abrasion
have been reported following MMC treatment for sebaceous
carcinoma and diffuse CIN.8 11 It is possible that the limbal
stem cell damage in these cases was related to the diffuse
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Frucht-Pery et al1 Conjunctival-corneal
intraepithelial neoplasia
17 0.02–0.04% MMC four times







Heigle et al3 Recurrent conjunctival
epithelial neoplasia
3 0.04% three times daily for 3




Wilson et al4 Conjunctival and corneal
epithelial dysplasia and
neoplasia
7 0.04% MMC four times daily for








Finger et al6 Conjunctival melanoma
and PAM with atypia
10 0.04% MMC qid for 28 days (4)





Demirci et al7 Conjunctival malignant
melanoma and PAM with
atypia
12 0.04% four times daily for 28
days (7)
Keratoconjunctivitis 12
0.04% four times daily for 7
days (5)
Focal corneal haze 1
Daniell et al2 Corneal conjunctival
intraepithelial neoplasia
20 0.02–0.04% MMC four times









Shields et al10 Diffuse conjunctival corneal
squamous cell carcinoma
10 0.04% MMC four times daily









Shields et al8 Sebaceous gland
carcinoma with conjunctival
pagetoid spread
4 0.04% MMC four times daily for








Recurrent corneal abrasion 1
Peripheral corneal pannus 1
Sacu et al12 Conjunctival malignant
melanoma
1 0.04% MMC four times daily for
8 weeks, two 28 days courses,
separated by 1 month
Intumescent cataract 1
Billing et al13 Corneal epithelial dysplasia 1 0.04% MMC four times daily for
2 weeks, 1 week on/1 week off
Punctal canalicular stenosis 1
Dudney et al11 Conjunctival corneal
intraepithelial neoplasia
1 0.04% MMC four times daily for
5 weeks, five 1 week courses
Recurrent non-healing
corneal epithelial defects/l
imbal stem cell deficiency
1
Kopp et al14 MM, PAM, SCC 14 0.04% MMC four times daily for
2–18 weeks, one to six 2 week
courses
Punctal canalicular stenosis 6
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neoplastic disease process or its previous surgical treatment
rather than to the MMC itself.
Serious complications of MMC have been reported but
were seen in the context of pterygium surgery where MMC
was applied to the bare sclera for 3–5 minutes via a soaked
sponge. Complications have included scleromalacia and
perforation, corneal melt, cataract, intractable glaucoma,
anterior uveitis, pyogenic granulomas, calcific scleral plaques,
and corneal ulcers.22 23 None of these serious complications
were observed in our study or in the series that have
employed one to five cycles of the four times a day for 7 day
regimen of topical MMC for ocular surface neoplasia.1 2 4 8 10
In two exenteration specimens of conjunctival melanoma
previously treated with MMC 0.04% four times a day for
7 days and 28 days respectively, no toxic effect was noted on
histology of the episclera, cornea, iris, ciliary body, lens,
sclera, or retina.7 This finding suggested that the usual
regimen of MMC for ocular surface neoplasia does not
penetrate deeper than the corneal or conjunctival sub-
epithelium. We therefore believe that allowing time for the
corneal epithelium to heal before commencing topical MMC
would be important although this was not evaluated in our
study.
In the largest study looking at complications of MMC in
the treatment of ocular surface neoplasia, allergic reaction
and puntal stenosis were the main complications noted.
Serious complications were not observed, suggesting the safe
use of MMC in mid-term evaluation. Long term study is
needed to determine if limbal stem cell failure will prove to
be a complication.
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